Jane Street Group, LLC Exelixis, Inc. Transaction History

Jane Street Group, LLC

$445 Billion
Q3 2024

A detailed history of Jane Street Group, LLC transactions in Exelixis, Inc. stock. As of the latest transaction made, Jane Street Group, LLC holds 361,216 shares of EXEL stock, worth $12.9 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

361,216

Previous 383,563 5.83%

Holding current value

$12.9 Million

Previous $8.62 Million 8.76%

% of portfolio

0.0%

Previous 0.01%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$21.96 - $27.6 $490,740 - $616,777	-22,347 Reduced 5.83%	361,216 $9.37 Million
Q2 2024 Aug 14, 2024	BUY	$20.34 - $23.73 $1.87 Million - $2.19 Million	92,115 Added 31.61%	383,563 $8.62 Million
Q1 2024 May 15, 2024	SELL	$20.17 - $23.93 $287,079 - $340,595	-14,233 Reduced 4.66%	291,448 $6.92 Million
Q4 2023 Feb 14, 2024	SELL	$19.25 - $24.13 $1.65 Million - $2.07 Million	-85,780 Reduced 21.91%	305,681 $7.33 Million
Q3 2023 Nov 14, 2023	BUY	$19.04 - $22.74 $2.65 Million - $3.17 Million	139,296 Added 55.24%	391,461 $8.55 Million
Q2 2023 Aug 14, 2023	SELL	$18.17 - $20.48 $3.81 Million - $4.29 Million	-209,425 Reduced 45.37%	252,165 $4.82 Million
Q1 2023 May 15, 2023	BUY	$16.3 - $19.41 $7.52 Million - $8.96 Million	461,590 New	461,590 $8.96 Million
Q3 2022 Nov 14, 2022	BUY	$15.68 - $22.27 $1.89 Million - $2.68 Million	120,439 Added 91.0%	252,789 $3.96 Million
Q2 2022 Aug 16, 2022	BUY	$17.44 - $23.16 $869,244 - $1.15 Million	49,842 Added 60.41%	132,350 $2.76 Million
Q1 2022 May 17, 2022	SELL	$17.03 - $22.67 $1.13 Million - $1.5 Million	-66,068 Reduced 44.47%	82,508 $1.87 Million
Q4 2021 Feb 15, 2022	BUY	$15.84 - $21.88 $591,829 - $817,502	37,363 Added 33.6%	148,576 $2.72 Million
Q3 2021 Nov 16, 2021	SELL	$16.3 - $21.14 $514,656 - $667,474	-31,574 Reduced 22.11%	111,213 $2.35 Million
Q2 2021 Aug 16, 2021	BUY	$17.95 - $25.56 $609,510 - $867,915	33,956 Added 31.2%	142,787 $2.6 Million
Q1 2021 May 18, 2021	SELL	$20.53 - $25.22 $783,465 - $962,445	-38,162 Reduced 25.96%	108,831 $2.46 Million
Q4 2020 Feb 17, 2021	BUY	$18.39 - $24.8 $684,236 - $922,733	37,207 Added 33.89%	146,993 $2.95 Million
Q3 2020 Nov 17, 2020	BUY	$20.67 - $26.94 $1.92 Million - $2.5 Million	92,732 Added 543.76%	109,786 $2.69 Million
Q2 2020 Aug 17, 2020	SELL	$16.46 - $27.42 $938 - $1,562	-57 Reduced 0.33%	17,054 $405,000
Q1 2020 May 15, 2020	SELL	$14.46 - $21.8 $1.67 Million - $2.51 Million	-115,242 Reduced 87.07%	17,111 $295,000
Q4 2019 Feb 14, 2020	BUY	$15.15 - $18.89 $981,462 - $1.22 Million	64,783 Added 95.88%	132,353 $2.33 Million
Q3 2019 Nov 14, 2019	BUY	$17.68 - $22.65 $737,804 - $945,207	41,731 Added 161.5%	67,570 $1.2 Million
Q2 2019 Aug 15, 2019	SELL	$18.93 - $24.75 $1.19 Million - $1.56 Million	-62,972 Reduced 70.91%	25,839 $553,000
Q1 2019 May 16, 2019	SELL	$19.6 - $24.76 $157,231 - $198,624	-8,022 Reduced 8.28%	88,811 $2.11 Million
Q4 2018 Feb 15, 2019	SELL	$13.65 - $21.8 $645,685 - $1.03 Million	-47,303 Reduced 32.82%	96,833 $1.91 Million
Q3 2018 Nov 14, 2018	BUY	$15.87 - $22.4 $1.4 Million - $1.98 Million	88,338 Added 158.32%	144,136 $2.55 Million
Q1 2018 May 15, 2018	BUY	$22.15 - $31.89 $342,837 - $493,593	15,478 Added 38.39%	55,798 $1.24 Million
Q4 2017 Feb 15, 2018	SELL	$24.23 - $30.93 $481,377 - $614,486	-19,867 Reduced 33.01%	40,320 $1.23 Million
Q3 2017 Nov 14, 2017	BUY	$23.35 - $29.24 $1.41 Million - $1.76 Million	60,187	60,187 $1.46 Million

Others Institutions Holding EXEL

# of Institutions

501

Shares Held

244M

Call Options Held

2.54M

Put Options Held

2.29M

View Full List

About EXELIXIS, INC.

Ticker EXEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 321,832,000
Market Cap $11.5B
Description
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...

More about EXEL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Jane Street Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Jane Street Group, LLC with notifications on news.

Account

Jane Street Group, LLC Exelixis, Inc. Transaction History